Avochato today announced a HIPAA compliant SMS messaging solution. It offers additional layers of security that allow healthcare companies to communicate with patients over SMS while following HIPAA requirements.
TheraCell Inc., a leading allograft solution company, today announced that it has completed the first surgical case using its TheraFuze DBF® Fiber Bullets™. This unique DBF fiber form is designed for minimal access delivery into expandable cages, revisions and other surgical applications.
Paragonix Technologies, the leading hypothermic cardiothoracic organ preservation provider, announced today the clinical and commercial launch of the LUNGguard™ Donor Lung Preservation System in both the USA and in Europe.
Simplivia is a leading global medical device developer and manufacturer of Closed System Transfer Devices (CSTDs). CSTDs are used to protect pharmacists, nurses, and other medical professionals in hospital settings from exposure to hazardous drugs, most often oncology drugs. They also ensure drug sterility to protect patients.
Nanomix, a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that XPRIZE has selected the company’s eLab® COVID-19 assay as a finalist in the XPRIZE Rapid COVID Testing competition.
Labcorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and Walgreens today announced that the Pixel by Labcorp™ At-Home COVID-19 Collection Kit is now available...
Aerus Medical formally announced the start of a double-blind two-year clinical study to evaluate the impact the Aerus Medical Guardian with ActivePure Technology can have on reducing nosocomial infections, or healthcare-associated infections, also known as HAIs, from surgical operating room procedures.
Abiomed (NASDAQ: ABMD) announces the first two patients in the world have been treated with the Abiomed Breethe OXY-1 System, a compact cardiopulmonary bypass system.
Minnetronix Medical, which partners with companies throughout the world to design, develop and manufacture medical device technology, today announced that it has been awarded a National Institutes of Health (NIH) granti for continued study of its proprietary Neurapheresis™ Cerebrospinal Fluid Treatment Platform.
Masimo (NASDAQ: MASI) today announced the findings of an abstract recently presented at ANESTHESIOLOGY® 2020, the Annual Meeting of the American Society of Anesthesiologists (ASA).